Recital 9, Regulation (EU) 2024/2221

In forcesince 6 Sep 2024

With regard to the renewal of the approvals of the active substances acequinocyl, emamectin, fatty acids C7 to C20 and pendimethalin, respectively, the Authority needs additional time to conclude the risk assessment carried out for these substances, including, where appropriate, a public consultation and a consultation of experts. Additional time is necessary for the Commission to adopt the ensuing risk management decision.